SHELTON, Conn., Aug. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and ...

Intensity Therapeutics (INTS) and The Swiss Group for Clinical Cancer Research or SAKK, announced that Andreas Mueller presented the final data from Intensity’s INVINCIBLE-2 Study and an overview / ...

Mid-2024, Intensity Therapeutics will start Phase 3 and Phase 2/3 trials respectively in soft tissue sarcoma and triple-negative breast cancer. INT230-6 has shown up to 95% tumor necrosis, prolonged ...

The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis, dose ranging, and safety The manuscript is ...

Intensity Therapeutics Inc. (NASDAQ:INTS) shares are trending on Friday. Check out the current price of INTS stock here. Shares of the biotechnology company rallied 394.9% in Thursday's regular ...

WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune system ...

The debate about how hard to push during exercise has persisted for decades, with fitness approaches swinging between high-intensity interval training and gentler, steady-state activities. However, ...

A pair of climate scientists are proposing a sixth category for hurricanes as climate change increasingly intensifies storms, according to a new research study. In a study published Monday in the ...

In heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following multiple prior lines of therapy, intratumoral INT230-6 achieved: A disease ...